Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A meta-analysis

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 9, 2010, Pages 1459-1466

  Younis, Naveed ^a   Williams, Steven ^a   Ammori, Basil ^b,c   Soran, Handrean ^d  

^a WYTHENSHAWE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^d MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aspirin; Cardiovascular disease; Diabetes mellitus; Meta analysis; Myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID;

ARTERY DISEASE; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COCHRANE LIBRARY; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG EFFECT; DRUG EFFICACY; HEART INFARCTION; HUMAN; HYPERTENSION; MEDLINE; META ANALYSIS; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL VASCULAR DISEASE; PRIMARY PREVENTION; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; HUMANS; PRIMARY PREVENTION;

EID: 77952685474     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003792538     Document Type: Article

References (49)

1. Wild S, Macleod F, McKnight J, et al. Impact of deprivation on cardiovascular risk factors in people with diabetes: an observational study. Diabet Med 2008;25:194-199
2. Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the US. Diabetes Care 2009;32:2225-2229
3. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995 -- 2025: prevalence, numerical estimates, and projections. Diabetes Care 1998;21:1414-1431
4. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
5. Schramm TK, Gislason GH, Kober L, et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008;117:1945-1954
6. Rytter L, Troelsen S, Beck-Nielsen H. Prevalence and mortality of acute myocardial infarction in patients with diabetes. Diabetes Care 1985;8:230-234
7. The DECODE Study Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003;26:688-696
8. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-2653
9. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
10. Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications 2001;15:44-54
11. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007;262:157-172
12. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003;46:733-749
13. Younis N, Sharma R, Soran H, et al. Glycation as an atherogenic modification of LDL. Curr Opin Lipidol 2008;19:378-384
14. Angiolillo DJ, Suryadevara S. Aspirin and clopidogrel: efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 2009;23:375-388
15. Natarajan A, Marshall SM, Worthley SG, et al. The presence of coronary artery disease increases platelet-dependent thrombosis in patients with type 2 diabetes mellitus. J Thromb Haemost 2008;6:2210-2213
16. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003;26:2181-2188
17. Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 2009;32:531-540
18. Angiolillo DJ, Capranzano P, Desai B, et al. Impact of P2Y(12) inhibitory effects induced by clopidogrel on platelet procoagulant activity in type 2 diabetes mellitus patients. Thromb Res 2009;124:318-322
19. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774 (Pubitemid 20194655)
20. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624-632
21. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860
22. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease. Ann Intern Med 2009;150:396-404
23. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388-391
24. IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes: recommendations for standard, comprehensive, and minimal care. Diabet Med 2006;23:579-593
25. American Diabetes Association. Standards of medical care in diabetes -- 2009. Diabetes Care 2009;32(Suppl 1):S13-61
26. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007;115:114-126
27. Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88-136
28. Royal College of Physicians of London. Type 2 Diabetes: National Clinical Guidelines for management in primary and secondary care (update). London: Royal College of Physicians; 2008
29. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy--I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106
30. Physician's health study: aspirin and primary prevention of coronary heart disease. N Engl J Med 1989;321:1825-1828
31. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293-1304
32. Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300:2134-2141
33. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:1840-1850
34. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-1762 (Pubitemid 28269185)
35. Sacco M, Pellegrini F, Roncaglioni MC, et al. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 2003;26:3264-3272
36. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
37. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-2016
38. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591
39. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998;317:703-713
40. Fateh-Moghadam S, Plockinger U, Cabeza N, et al. Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 2005;42:99-103
41. Watala C. Blood platelet reactivity and its pharmacological modulation in (people with) diabetes mellitus. Curr Pharm Des 2005;11:2331-2365
42. Michelson AD, Cattaneo M, Eikelboom JW, et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost 2005;3:1309-1311
43. Anfossi G, Russo I, Trovati M. Resistance to aspirin and thienopyridines in diabetes mellitus and metabolic syndrome. Curr Vasc Pharmacol 2008;6:313-328
44. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-1599
45. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004;113:101-113
46. Takahashi S, Ushida M, Komine R, et al. Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 2007;119:517-524
47. Early Treatment Diabetic Retinopathy Study Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268:1292-1300
48. A Study of Cardiovascular Events in Diabetes (ASCEND). Available from: http://www.cstu.ox.ac.uk/ascend/ [Last accessed 15 January 2010]
49. De Berardis G, Sacco M, Evangelista V, et al. Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 2007;8:21-30